^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

arcotatug tavatecan (IBI-343)

i
Other names: IBI-343, IBI343
Company:
Innovent Biologics
Drug class:
Topoisomerase I inhibitor, CLDN18.2-targeted antibody-drug conjugate
Related drugs:
Phase 2
Zhejiang University
Not yet recruiting
Last update posted :
01/13/2025
Initiation :
01/01/2025
Primary completion :
01/01/2027
Completion :
01/01/2028
CLDN18
|
gemcitabine • albumin-bound paclitaxel • arcotatug tavatecan (IBI-343)
Phase 2
Harbin Medical University
Not yet recruiting
Last update posted :
03/20/2024
Initiation :
03/15/2024
Primary completion :
12/31/2025
Completion :
12/31/2025
CLDN18
|
CLDN18.2 expression
|
Tyvyt (sintilimab) • arcotatug tavatecan (IBI-343)
Phase 1
Innovent Biologics (Suzhou) Co. Ltd.
Recruiting
Last update posted :
11/11/2022
Initiation :
10/26/2022
Primary completion :
05/31/2024
Completion :
10/31/2024
CLDN18
|
arcotatug tavatecan (IBI-343)